波士顿科学公司简介2013精编版
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
• 通过持续改善我们现有的产品、不断的研发新的技术, 以
减少风险, 损伤, 费用, 手术时间和术后调养來达到的。
Boston Scientific Corporation Confidential
3
John Abele Co-Founder
Pete Nicholas Chairman of the Board
部分产品系列
Detachable Coils
Balloons
Grafts
Enteral Feeding
Ablation
Cardiac Mapping
Embolics
Stents
Stone Retrieval
Embolic Protection
Biopsy Systems
Peripheral Dilatation
John Tobin President and CEO
Boston Scientific Corporation Confidential
4
引领介入技术的发展
• 1979
波士顿科学的创始人John Abele和Pete
Nicholas成立公司。
• 1980-1990 公司在打开国际市场的同时，通过收购与兼并、
Product Priorities that will shape our future
Cardiac Rhythm Management (CRM)
Cameron Health cardioverter defibrillator
Carotid Stent
EndoTex NexStent 1 Carotid Stent
Neurovascular Endosurgery Neuromodulation
Implantable Cardioverter Defibrillators Wireless Remote Patient Monitoring Drug-Eluting Stents Balloon Catheters Guide Wires & Catheters Diagnostic Catheters Atherectomy IVUS Detachable Coils Peripheral Vascular/Nonvascular Stents AAA Grafts GI Metal Stents Biliary Devices GI Biopsy Devices GI Dilation Balloons Pain Management Cochlear Implants
Ureteral Stents
Catheters / Guidewires
Neuro-stimulation
Boston Scientific Corporation Confidential
9
Endosurgery Group
Revenue Trend by Business ($Millions)
• 拥护和发展微创介入技术,以提高
病人的治疗质量及卫生保健的生产力。
• This is accomplished through the continuing refinement of existing
products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare.
Phase I Less-Invasive Medicine Pioneer/Leader
Phase II Strategic Mass Phase III Stent Integration (Via Acquisitions) & Drug-Eluting Stent Leadership
Boston Scientific Corporation Confidential
全球市场占 有率排名
2 1 2* 1 2 2 1 1 1 1 1 1 1 1 1 2 2
* #1 share in the U.S.
Boston Scientific Corporation Confidential
8
Over 25 years of Innovation has led to a broad portfolio of more than 15,000 products
战略性的
并购过程
3,476
2,919
2,842
2,673
2,664
2,234
1,831 1,551
1,191
新的 里程碑
Phase IV CRM
Integration
2
3
8
13 16
22 31 47
71 99 116 159 230 315 380 449
'79 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06
Boston Scientific Corporation Confidential
5
强烈使命感铸就一段成长的传奇
全球介入医疗领域的领导者
Revenue ($Millions)
BSC acquires Guidant Corp.
7,821
TAXUS Express U.S. FDA approval
Medtronic 6%
Guidant 7%
Other 9%
BSC 43%
Endosurgery
(Endoscopy, Oncology, Urology, Gynecology)
AMS 4%
Cytyc 3%
J&J 3%
Olympus 5%
Conmed 3%
Cook 9%
BSC 35%
J&J 35%
波士顿科学公司简介 TOPU,Owen
波士顿科学全球的机构
直销地区
• 总部设在美国麻省波士顿地区的内提克ቤተ መጻሕፍቲ ባይዱNatick
• 在40国家直接进行销售; 全球雇有17,500+员工
• 16个主要生产地在美国, 爱尔兰和墨西哥
Boston Scientific Corporation Confidential
• 2003-2004 公司上市了许多革命性产品，包括药物释放冠脉
支架系，Matrix可脱弹簧圈等， 员工增加到15,000人
• 2006-2008 公司收购Guidant，销售额突破80亿美元，员工
人数超过2万人。
• 2010-2012 公司全球员工超过25000人，在全球排名财富500
强NO.335.
Stone Disease • Uterine Fibroids & Menorrhagia
Solutions
• Enternal Feeding Procedures • GI Dilation/Stenting • Microwave Dilation • Endometrial Ablation • Mid-Urethral Sling • Biliary, Urinary Drainage
Endovascular Aortic Repair (EVAR)
TriVascular AAA Stent Graft 1
Next-Generation Drug-Eluting Stents
TAXUS® Liberté ™ 2 Drug-Eluting Stent
电生理
ELECTROPHYSIOLOGY
心脏介入
CARDIOVASCULAR
妇科介入
GYNECOLOGY
泌尿介入
UROLOGY
7
不懈的努力让我们成为了各领域的领导者
波士顿产品组
产品分类
Cardiac Rhythm Management (CRM) Interventional Cardiology
2002
2003
2004
2005
2001
2002
2003
2004
2005
At year-end 2005: 7,800+ applications pending worldwide
Boston Scientific Corporation Confidential
12
The result of our Hybrid Model is a Robust Product Pipeline
• 90%+ of sales from market leading products • Represents 72% of BSC total business
Bard 14%
Others 24%
• 75% of sales from market leading products • Represents 20% of BSC total business
2
波士顿科学的使命
• To improve the quality of patient care and the productivity of health
care delivery through the development and advocacy of lessinvasive medical procedures.
Boston Scientific Corporation Confidential
Source: BSC internal estimates
11
BSC has made significant internal R&D investments to champion new ideas and products into new markets
6
微创伤技术对人体的应用
神经调节
NEUROMODULATION
外周血管介入
PERIPHERAL VASCULAR
血管外科
VASCULAR SURGERY
肿瘤介入
ONCOLOGY
内镜术
ENDOSCOPY
Boston Scientific Corporation Confidential
神经血管介入
NEUROVASCULAR
Oncology Urology/Gynecology Endoscopy
852
143 196
972
166 226
1,088
186 261
1,228
207 13.0% CAGR
324
513
580
641
697
2002
2003
2004
2005
Medical Conditions
• Malignant & Benign Tumors • Gastrointestinal Diseases • Gastrointestinal Cancers • Incontinence • Abscesses • End Stage Renal Disease • Benign Prostatic Hyperplasia • Gallstones & Urinary
Prolieve™ Thermodilatation System
Boston Scientific Corporation Confidential
10
We Achieve Global Leadership in our Key Markets
Interventional Cardiology
产品开发来扩大产品线。
• 1990-2000 公司收购与兼并了超过15家公司，产品从3,000种
激增到约10,000种。并于1992年在美国纽约证券交易所上市股 票。雇员从3,000人增加到9,000人。
• 2000-2003 波士顿科学公司大大增加了对研发的投资，专注
于开发革命性的科技产品，如药物释放冠脉支架。同时收购与 联合了20家公司。
New Product Development
Delivering what’s next.TM
R&D Investment 研究与开发
$Millions
$680
$569
$452
$275
$343
U.S. Patents Issued 美国专利权
2,535
2,892
3,307
3,617
4,016
2001
6,283
John Abele and Pete Nicholas partner to form Boston Scientific
BSC acquires eight companies in two years
BSC goes public with IPO on NYSE
股票上市
5,624 First clinical trial of drugeluting stent
减少风险, 损伤, 费用, 手术时间和术后调养來达到的。
Boston Scientific Corporation Confidential
3
John Abele Co-Founder
Pete Nicholas Chairman of the Board
部分产品系列
Detachable Coils
Balloons
Grafts
Enteral Feeding
Ablation
Cardiac Mapping
Embolics
Stents
Stone Retrieval
Embolic Protection
Biopsy Systems
Peripheral Dilatation
John Tobin President and CEO
Boston Scientific Corporation Confidential
4
引领介入技术的发展
• 1979
波士顿科学的创始人John Abele和Pete
Nicholas成立公司。
• 1980-1990 公司在打开国际市场的同时，通过收购与兼并、
Product Priorities that will shape our future
Cardiac Rhythm Management (CRM)
Cameron Health cardioverter defibrillator
Carotid Stent
EndoTex NexStent 1 Carotid Stent
Neurovascular Endosurgery Neuromodulation
Implantable Cardioverter Defibrillators Wireless Remote Patient Monitoring Drug-Eluting Stents Balloon Catheters Guide Wires & Catheters Diagnostic Catheters Atherectomy IVUS Detachable Coils Peripheral Vascular/Nonvascular Stents AAA Grafts GI Metal Stents Biliary Devices GI Biopsy Devices GI Dilation Balloons Pain Management Cochlear Implants
Ureteral Stents
Catheters / Guidewires
Neuro-stimulation
Boston Scientific Corporation Confidential
9
Endosurgery Group
Revenue Trend by Business ($Millions)
• 拥护和发展微创介入技术,以提高
病人的治疗质量及卫生保健的生产力。
• This is accomplished through the continuing refinement of existing
products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare.
Phase I Less-Invasive Medicine Pioneer/Leader
Phase II Strategic Mass Phase III Stent Integration (Via Acquisitions) & Drug-Eluting Stent Leadership
Boston Scientific Corporation Confidential
全球市场占 有率排名
2 1 2* 1 2 2 1 1 1 1 1 1 1 1 1 2 2
* #1 share in the U.S.
Boston Scientific Corporation Confidential
8
Over 25 years of Innovation has led to a broad portfolio of more than 15,000 products
战略性的
并购过程
3,476
2,919
2,842
2,673
2,664
2,234
1,831 1,551
1,191
新的 里程碑
Phase IV CRM
Integration
2
3
8
13 16
22 31 47
71 99 116 159 230 315 380 449
'79 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06
Boston Scientific Corporation Confidential
5
强烈使命感铸就一段成长的传奇
全球介入医疗领域的领导者
Revenue ($Millions)
BSC acquires Guidant Corp.
7,821
TAXUS Express U.S. FDA approval
Medtronic 6%
Guidant 7%
Other 9%
BSC 43%
Endosurgery
(Endoscopy, Oncology, Urology, Gynecology)
AMS 4%
Cytyc 3%
J&J 3%
Olympus 5%
Conmed 3%
Cook 9%
BSC 35%
J&J 35%
波士顿科学公司简介 TOPU,Owen
波士顿科学全球的机构
直销地区
• 总部设在美国麻省波士顿地区的内提克ቤተ መጻሕፍቲ ባይዱNatick
• 在40国家直接进行销售; 全球雇有17,500+员工
• 16个主要生产地在美国, 爱尔兰和墨西哥
Boston Scientific Corporation Confidential
• 2003-2004 公司上市了许多革命性产品，包括药物释放冠脉
支架系，Matrix可脱弹簧圈等， 员工增加到15,000人
• 2006-2008 公司收购Guidant，销售额突破80亿美元，员工
人数超过2万人。
• 2010-2012 公司全球员工超过25000人，在全球排名财富500
强NO.335.
Stone Disease • Uterine Fibroids & Menorrhagia
Solutions
• Enternal Feeding Procedures • GI Dilation/Stenting • Microwave Dilation • Endometrial Ablation • Mid-Urethral Sling • Biliary, Urinary Drainage
Endovascular Aortic Repair (EVAR)
TriVascular AAA Stent Graft 1
Next-Generation Drug-Eluting Stents
TAXUS® Liberté ™ 2 Drug-Eluting Stent
电生理
ELECTROPHYSIOLOGY
心脏介入
CARDIOVASCULAR
妇科介入
GYNECOLOGY
泌尿介入
UROLOGY
7
不懈的努力让我们成为了各领域的领导者
波士顿产品组
产品分类
Cardiac Rhythm Management (CRM) Interventional Cardiology
2002
2003
2004
2005
2001
2002
2003
2004
2005
At year-end 2005: 7,800+ applications pending worldwide
Boston Scientific Corporation Confidential
12
The result of our Hybrid Model is a Robust Product Pipeline
• 90%+ of sales from market leading products • Represents 72% of BSC total business
Bard 14%
Others 24%
• 75% of sales from market leading products • Represents 20% of BSC total business
2
波士顿科学的使命
• To improve the quality of patient care and the productivity of health
care delivery through the development and advocacy of lessinvasive medical procedures.
Boston Scientific Corporation Confidential
Source: BSC internal estimates
11
BSC has made significant internal R&D investments to champion new ideas and products into new markets
6
微创伤技术对人体的应用
神经调节
NEUROMODULATION
外周血管介入
PERIPHERAL VASCULAR
血管外科
VASCULAR SURGERY
肿瘤介入
ONCOLOGY
内镜术
ENDOSCOPY
Boston Scientific Corporation Confidential
神经血管介入
NEUROVASCULAR
Oncology Urology/Gynecology Endoscopy
852
143 196
972
166 226
1,088
186 261
1,228
207 13.0% CAGR
324
513
580
641
697
2002
2003
2004
2005
Medical Conditions
• Malignant & Benign Tumors • Gastrointestinal Diseases • Gastrointestinal Cancers • Incontinence • Abscesses • End Stage Renal Disease • Benign Prostatic Hyperplasia • Gallstones & Urinary
Prolieve™ Thermodilatation System
Boston Scientific Corporation Confidential
10
We Achieve Global Leadership in our Key Markets
Interventional Cardiology
产品开发来扩大产品线。
• 1990-2000 公司收购与兼并了超过15家公司，产品从3,000种
激增到约10,000种。并于1992年在美国纽约证券交易所上市股 票。雇员从3,000人增加到9,000人。
• 2000-2003 波士顿科学公司大大增加了对研发的投资，专注
于开发革命性的科技产品，如药物释放冠脉支架。同时收购与 联合了20家公司。
New Product Development
Delivering what’s next.TM
R&D Investment 研究与开发
$Millions
$680
$569
$452
$275
$343
U.S. Patents Issued 美国专利权
2,535
2,892
3,307
3,617
4,016
2001
6,283
John Abele and Pete Nicholas partner to form Boston Scientific
BSC acquires eight companies in two years
BSC goes public with IPO on NYSE
股票上市
5,624 First clinical trial of drugeluting stent